Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.

Curr Oncol

Division of Hematology and Medical Oncology, Knight Cancer Institute, Department of Preventive Medicine and Public Health, and Center for Health Care Ethics, Oregon Health and Science University, Portland, OR, U.S.A.

Published: December 2019

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927779PMC
http://dx.doi.org/10.3747/co.26.4845DOI Listing

Publication Analysis

Top Keywords

multiplicity marginal
4
marginal benefits
4
benefits bevacizumab
4
bevacizumab malignant
4
malignant solid
4
solid tumours
4
multiplicity
1
benefits
1
bevacizumab
1
malignant
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!